Daclatasvir Medications

Daclatasvir Info

What is Daclatasvir?

Daclatasvir is a direct-acting antiviral medication that belongs to the class of NS5A inhibitors. Its main role is to stop the hepatitis C virus from copying itself inside liver cells. You will find daclatasvir as the active ingredient in several branded and generic products, such as Daklinza and the generic medicine simply named Daclatasvir.

Medications with Daclatasvir

• Daklinza - the proprietary brand, supplied as film-coated tablets.
• Daclatasvir - the generic version, also available as tablets in a range of strengths.

Both products are taken orally and are marketed throughout the United Kingdom. While the active ingredient is the same, the tablets may differ in size, colour and packaging, and they can be combined with other antiviral agents in fixed-dose regimens.

What Does Daclatasvir Treat?

• Chronic hepatitis C infection - the medication helps clear the virus from the bloodstream, reducing liver inflammation and the risk of long-term damage.
• Specific hepatitis C genotypes - daclatasvir is effective against several viral genotypes, particularly genotype 1 and genotype 3, when used as part of a combination regimen.
• Co-infection with HIV - in patients who have both hepatitis C and HIV, daclatasvir may be included in treatment plans under specialist supervision.

These uses are approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for adult patients. Off-label applications are rare and should only be considered by a specialist.

How Daclatasvir Works

Daclatasvir targets a protein called NS5A that the hepatitis C virus needs to assemble new virus particles. By binding to this protein, the drug hampers the virus’s ability to replicate, allowing the immune system to clear the infection more effectively. The antiviral effect begins shortly after the tablet is absorbed, but the full benefit is seen over the course of the prescribed treatment period.

Safety Information

Common Side Effects

• Mild headache
• Fatigue or feeling unusually tired
• Nausea or mild stomach upset
• Slight dizziness

These reactions are usually short-lived and resolve without needing medical intervention. If they persist, reviewing the product information for the specific medication is advisable.

Serious Reactions

Rare but important warnings include:

• Severe rash or skin blistering
• Signs of an allergic reaction such as swelling of the face, lips or tongue
• Sudden shortness of breath or difficulty breathing

Seek urgent medical help if any of these symptoms develop.

Who Should Be Cautious

• Pregnancy and breastfeeding - the safety of daclatasvir during pregnancy has not been firmly established; women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their specialist.
• Severe liver impairment - patients with advanced liver disease may require special consideration before using daclatasvir-containing regimens.
• Known hypersensitivity - anyone who has reacted to daclatasvir or any of its excipients should avoid products containing the ingredient.

Interaction Awareness

Daclatasvir can interact with several other medicines, including:

• Certain antiretroviral drugs used for HIV
• Strong enzyme-inducing agents such as some antiepileptics
• St. John’s wort (a herbal supplement)

Alcohol consumption does not directly affect daclatasvir’s action, but heavy drinking can worsen liver health. Driving or operating machinery is generally safe, although dizziness may be an issue for some individuals. For a complete list of possible interactions, refer to the individual medication pages.

What to Know Before Using

Store tablets in a dry place away from direct sunlight, at temperatures not exceeding 25 °C. Typical treatment courses last several weeks, depending on the combination regimen prescribed. Because formulations differ, always read the specific product’s leaf-let for storage instructions and any special handling advice. For detailed usage, dosing, administration, refer to your specific medication's information.

Key Terms

NS5A inhibitor: A drug that blocks the NS5A protein, stopping hepatitis C virus replication.

Direct-acting antiviral (DAA): A class of medicines that target specific steps in the hepatitis C virus life-cycle.

Genotype: A classification of hepatitis C based on genetic differences; treatment choice can depend on the genotype.

Important Notice

This article offers general educational information about daclatasvir as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing daclatasvir may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.